Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing
Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpointAnalyses of the data, including prespecified exploratory endpoints, are ongoingContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a
A medicine test did not show the results the company hoped for. The team is still looking at the data to see if other parts worked well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.